We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Clarifies Endpoints in NSCLC Clinical Trials
FDA Clarifies Endpoints in NSCLC Clinical Trials
May 7, 2015
While overall survival remains the desired endpoint in treating non-small cell lung cancer, progression-free survival may suffice as the primary endpoint, the FDA says.